network member

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

676 North St. Clair Street, 21st Floor, Chicago, IL 60611 - USA
Maggie Daley Center for Women’s Cancer Care, Prentice Women's Hospital
250 E Superior, 4th Floor, Chicago, IL 60611 - USA
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

About Network Member

First established at Northwestern University in 1974, the center was dedicated as the Robert H. Lurie Cancer Center of Northwestern University in 1991 through a gift of endowment from Ann and Robert H. Lurie. The center’s title was modified in 1997, when the National Cancer Institute (NCI) awarded the Lurie Cancer Center the “comprehensive” designation, reflecting the center’s dedication to the highest standards of cancer research, patient care, education, and community outreach. Today, the Lurie Cancer Center is one of only 41 NCI-designated “comprehensive” cancer centers in the nation. In addition, the Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 25 of the world’s leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. It also is part of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities. The Lurie Cancer Center is affiliated with four teaching hospitals in Chicago — Northwestern Memorial Hospital, Ann & Robert H. Lurie Children’s Hospital of Chicago, the Rehabilitation Institute of Chicago, and the Jesse Brown Veteran’s Affairs Medical Center – treating more than 10,000 new cancer cases each year. Website: Robert H. Lurie Comprehensive Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Cary Passaglia, CCRP
Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Cancer areas:Head and Neck
Masonic Cancer Center, University of Minnesota
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

BTCRC-LYM20-463

A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Cancer areas:Lymphoma
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Cleveland Clinic Cancer Center
Columbia University Irving Medical Center
Fox Chase Cancer Center
Georgetown Lombardi Comprehensive Cancer Center
Penn Medicine Abramson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Winship Cancer Institute of Emory University
Yale Cancer Center
Enrollment Closed

HCRN-MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma
Cancer areas:Melanoma
Columbia University Irving Medical Center
Georgetown Lombardi Comprehensive Cancer Center
MD Anderson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
UC San Francisco
Enrollment Closed

BTCRC-BRE18-337

Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
Cancer areas:Breast
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-GI15-067

A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067
Cancer areas:Pancreatic
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Enrollment Closed

BTCRC-LUN19-396

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Summit Health Cancer Center
The Ohio State University
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center